Burcon NutraScience Corporation reports developments tied to plant-based protein ingredients for the food and beverage industry. Company updates cover commercialization of high-performance protein products such as Peazzaz®, FavaPro and Puratein®, production scale-up, customer adoption across beverage, nutrition and plant-based food applications, and work with manufacturing partners to support demand.
Recurring news also includes operating and financial results, convertible-debenture financing, shareholder voting matters, warrant amendments, board changes and other governance actions. Burcon's communications frequently reference its patent portfolio for proteins derived from pea, canola, soy, hemp, sunflower and other plant sources.
Burcon NutraScience (BRCNF) updated its commercial guidance and reported shareholder meeting results on September 24, 2026. Burcon now expects at least $6 million in revenue for calendar 2026 and an annualized revenue run rate of at least $10 million as it exits the year. It also expects to achieve positive cash flow in calendar 2027.
The revised 2026 outlook reflects the timing of its production ramp and additional equipment, infrastructure and process improvements. Burcon said the adjustment shifts the timing of revenue it previously anticipated. Shareholders elected all six board nominees and approved resolutions related to a proposed convertible debenture financing of up to $21 million in principal proceeds. The financing remains subject to final Toronto Stock Exchange approval and other closing conditions. Burcon intends to use a significant portion of the proceeds for its Galesburg production facility.
Burcon NutraScience (BRCNF) will hold its virtual annual general and special meeting on September 24, 2026, after postponing the previously scheduled September 16, 2026 meeting to allow shareholders time to review an amended and restated management proxy circular dated September 4, 2026.
The circular reflects an upsized non-brokered private placement of convertible debentures, increased from $8.1 million to $21 million in aggregate principal amount following strong investor interest. Insider participation is unchanged. An existing prepayment right is replaced with an accelerated conversion right, allowing the company to force conversion after four months and one day if the volume-weighted average share price is at or above $3.20 for 14 consecutive trading days, with 15 days’ notice. Benchmark Company is engaged as exclusive placement agent on a best efforts basis, earning cash fees of 5.0% or 8.0% of gross proceeds from specified investor groups, excluding insiders. The TSX has conditionally approved the upsized placement, which remains subject to shareholder approval and limits insider participation to not more than 25% of market capitalization under MI 61-101 exemptions.
Burcon NutraScience (OTCQB: BRCNF) reported fiscal 2027 first quarter revenue of $1.3 million for the three months ended June 30, 2026, up 273% year-over-year and 54% sequentially, driven by growing production and sales from its Galesburg plant-based protein facility.
The company recorded a net loss of $3.8 million or $0.30 per share versus a $3.5 million loss a year earlier, and used $2.4 million in operating cash. As of June 30, 2026, Burcon held $0.9 million in cash and had negative working capital of $11.2 million, largely due to a senior secured loan maturing December 17, 2026; $3.0 million remains undrawn on its second tranche.
To bolster liquidity, Burcon obtained a $1.4 million short-term related-party loan and announced a non-brokered private placement of convertible debentures for up to $8.1 million, bearing 15% annual interest and convertible at $1.60 per share or pre-funded warrant, subject to TSX and disinterested shareholder approval at the September 16, 2026 AGSM.
Burcon NutraScience (OTCQB: BRCNF) will host an investor conference call and webcast on Wednesday, August 12, 2026 at 5:00 p.m. Eastern time to discuss its fiscal 2027 first-quarter results, which will be released earlier that day. The webcast link and replay will be available via Burcon’s website under “Presentations,” with participation also possible by phone using North American toll-free and international dial-in numbers and conference ID 54552.
Burcon (OTCQB:BRCNF, TSX:BU) reported fiscal 2026 results for the year ended March 31, 2026, highlighting its shift to commercial production.
Revenue reached $2.3 million, up about 494% year-over-year, with a $14.3 million net loss, increased cash burn, new financings and a senior loan maturity extension.
Burcon (OTCQB:BRCNF) will host an investor conference call and webcast on Wednesday, June 24, 2026 at 5:00 p.m. Eastern time to discuss fiscal year 2026 results for the year ended March 31, 2026.
The webcast link is available under “Presentations” on Burcon’s website, with an archived replay.
Burcon (OTCQB:BRCNF) reported accelerating commercialization, with approximately 50% sales growth versus the prior quarter and a new production record with partner Re ProMan.
Recent output exceeded Burcon’s calendar Q1 daily average by about 60%. Management notes growing demand for its pea, fava and canola proteins and anticipates needing additional capital for expansion and working capital.
Burcon (OTCQB: BRCNF) appointed Chris Bunio to its board effective April 29, 2026, and announced departures of directors Jeanne McCaherty and Richard Nazur Jr..
Bunio brings nearly 30 years in technology, founded and operationalized TheoryMesh in 2021, and previously spent 18 years at Microsoft in global senior roles. McCaherty joined Burcon in July 2021; Nazur joined in September 2025.
Burcon (OTCQB: BRCNF) closed the final tranche of a non‑brokered private placement of convertible debentures for an aggregate principal amount of $6.9 million on April 27, 2026. The final tranche raised $2.9 million, with insiders subscribing about $4.4 million in aggregate.
The Company received approximately $2.35 million cash from the final tranche after offsetting $546,678 payable to an entity related to an insider. Proceeds will fund inventory, labor, production capability, infrastructure planning, loan repayments and general corporate purposes.
Burcon (OTCQB: BRCNF) reported operational and commercial progress on April 20, 2026. The company achieved record production, raising average daily output by approximately 40% versus the calendar Q1 average, and expanded to more than 20 buying customers across multiple food and beverage categories. Burcon and manufacturing partner RE ProMan are evaluating additional capacity expansion to meet rising demand across products such as Peazzaz, FavaPro and Puratein.
Management said the milestones support scaling toward 2026 goals while focusing on efficient growth and customer onboarding.